Blend identity and evidence limits
Tesamorelin + Ipamorelin Blend
How this blend differs from prescription tesamorelin and what the cited component sources actually cover.
Source and review status
Identity unresolved
Identity search checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Prescription medicine versus mixture
Prescription tesamorelin is a growth-hormone-releasing-factor analogue used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight loss. Adding ipamorelin creates a different formulation that is not assessed by that monograph.
Sources: MedlinePlus / American Society of Health-System Pharmacists
What cannot be carried over
The tesamorelin reference identifies medicine-specific precautions, including pregnancy, cancer history and glucose-related concerns. It does not establish the efficacy, compatibility or monitoring requirements of a tesamorelin and ipamorelin blend.
Sources: MedlinePlus / American Society of Health-System Pharmacists
The additional evidence gap
FDA’s ipamorelin assessment reports inadequate safety information for some injectable routes, and immune-response and impurity concerns. The existence of a prescription medicine containing one ingredient cannot resolve the added ingredient’s risks.
Sources: U.S. Food and Drug Administration
The blend’s ratio, finished formulation and combination-specific outcomes remain unverified. A product label or hormone measurement alone would not answer those questions.
Published sources
- Tesamorelin Injection
MedlinePlus / American Society of Health-System Pharmacists. Revised 15 July 2025; accessed 6 September 2026.
Supports: Prescription tesamorelin’s HIV-associated lipodystrophy indication and warning context. Does not assess an ipamorelin mixture.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
U.S. Food and Drug Administration. Current FDA reference; accessed 6 September 2026.
Supports: Named substance and route-specific safety findings. Ingredient assessments do not validate a finished blend.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Identity and evidence limits documented | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.